NCT04617067View on ClinicalTrials.gov

Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Advanced Pancreatic Cancer
Interventions
DRUG

Paricalcitol

Paricalcitol 12mcg, administered orally on every day of each 28-day cycle.

DRUG

Gemcitabine (GEM) and Nab-paclitaxel

GEM (at 1,000 mg/m2) and Nab-paclitaxel (at 125 mg/m2 of bodysurface area), administered weekly for 3 of every 4 weeks (on days 1, 8 and 15 only).

Trial Locations (6)

D24 NR04

Tallaght University Hospital, Dublin

D04 T6F4

St. Vincent's University Hospital, Dublin

D09V2N0

Beaumont Hospital, Dublin

T12 DC4A

Cork University Hospital, Cork

V94 F858

University Hospital Limerick, Limerick

X91 ER8E

University Hospital Waterford, Waterford

All Listed Sponsors
lead

Cancer Trials Ireland

NETWORK

NCT04617067 - Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter